Dél-afrikai Köztársaság - angol - South African Health Products Regulatory Authority (SAHPRA)

eli lilly (s.a.) (pty) ltd - tablet - see ingredients - each tablet contains raloxifene hydrochloride 60,0 mg

Dél-afrikai Köztársaság - angol - South African Health Products Regulatory Authority (SAHPRA)

teva pharmaceuticals (pty) ltd - capsules - see ingredients - each capsule contains omeprazole 20,0 mg

Dél-afrikai Köztársaság - angol - South African Health Products Regulatory Authority (SAHPRA)

reckitt benckinser pharmaceuticals (pty) ltd - suspension - see ingredients - each 10,0 ml suspension contains sodium alginate 500,0 mg

Dél-afrikai Köztársaság - angol - South African Health Products Regulatory Authority (SAHPRA)

reckitt benckinser pharmaceuticals (pty) ltd - suspension - see ingredients - each 10,0 ml suspension contains calcium carbonate 325,0 mg sodium alginate 500,0 mg sodium bicarbonate 213,0 mg

Dél-afrikai Köztársaság - angol - South African Health Products Regulatory Authority (SAHPRA)

teva pharmaceuticals (pty) ltd - tablet - see ingredients - each tablet contains desloratadine 5,0 mg

Dél-afrikai Köztársaság - angol - South African Health Products Regulatory Authority (SAHPRA)

teva pharmaceuticals (pty) ltd - tablet - see ingredients - each tablet contains abiraterone 250,0 mg

Egyesült Államok - angol - NLM (National Library of Medicine)

sun products corporation - triclosan (unii: 4nm5039y5x) (triclosan - unii:4nm5039y5x) -

Egyesült Államok - angol - NLM (National Library of Medicine)

sun products corporation - triclosan (unii: 4nm5039y5x) (triclosan - unii:4nm5039y5x) -

Izrael - angol - Ministry of Health

dexcel ltd, israel - teriparatide - solution for injection - teriparatide 250 mcg/ml - teriparatide - treatment of postmenopausal women with osteoporosis at high risk for fracture: terrosa is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy. in postmenopausal women with osteoporosis,terrosa increases bmd reduces the risk of vertebral and nonvertebral fractures . increase of bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture: terrosa is indicated to increase bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy. treatment of men and women with glucocorticoid-induced osteoporosis at high risk for fracture: terrosa is indicated for the treatment of men and women with osteoporosis associated with sustained systemic glucocorticoid therapy (daily dosage equivalent to 5 mg or greater of prednisone) at high risk for fracture, defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy.

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - raloxifene hydrochloride -